



AMERICAN
THYROID
ASSOCIATION
FOUNDED 1923

2010-2011

President

Gregory A. Brent, M.D. (2010-2011)
Los Angeles, California

Secretary/Chief Operating Officer

Richard T. Kloos, M.D. (2007-2011)
Columbus, Ohio

Treasurer

David H. Sarne, M.D. (2007-2013)
Chicago, Illinois

President-Elect

James A. Fagin, M.D. (2010-2011)
New York, New York

Secretary-Elect

John C. Morris, M.D. (2010-2011)
Rochester, Minnesota

Past-President

Terry F. Davies, M.D. (2010-2011)
New York, New York

Directors

Ian D. Hay, M.D., Ph.D. (2007-2011)
Rochester, Minnesota

R. Michael Tuttle, M.D. (2007-2011)
New York, New York

M. Carol Greenlee, M.D. (2008-2012)
Grand Junction, Colorado

Peter A. Kopp, M.D. (2009-2013)
Chicago, Illinois

Elizabeth N. Pearce, M.D. (2009-2013)
Boston, Massachusetts

Victor J. Bernet, M.D. (2010-2014)
Jacksonville, Florida

Gerard M. Doherty, M.D. (2010-2014)
Ann Arbor, Michigan

Sissy M. Jhiang, Ph.D. (2010-2014)
Columbus, Ohio

Executive Director

Barbara R. Smith, CAE

Headquarters Office

American Thyroid Association
6066 Leesburg Pike, Suite 550
Falls Church, Virginia 22041
Phone: 703 998-8890
Fax: 703 998-8893
E-mail: bsmith@thyroid.org

ATA Board of Directors and Executive Staff Conflict of Interest Disclosure Statement

Conflict of Interest Disclosures to include significant financial and competing interests, such as: funded research, consultancies (paid or unpaid) editorial and non-profit boards, grant support.

Victor J. Bernet, MD discloses no significant financial interests or other relationships with commercial interests.

Gregory A. Brent, MD discloses no significant financial interests or other relationships with commercial interests.

Terry F. Davies, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Board member, KRONUS, Inc.

Gerard M. Doherty, MD discloses no significant financial interests or other relationships with commercial interests.

James A. Fagin, MD discloses no significant financial interests or other relationships with commercial interests.

M. Carol Greenlee, MD discloses no significant financial interests or other relationships with commercial interests.

Sissy M. Jhiang, PhD discloses no significant financial interests or other relationships with commercial interests.

Ian D. Hay, MD, PhD discloses no significant financial interests or other relationships with commercial interests.

Richard T. Kloos, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Grants/Research Support: Bayer, Eisai, Exelixis, Onyx, Veracyte; Consulting (with approval from the ATA Board of Directors and without honoraria): AstraZeneca, Bayer, Exelixis, Novo Nordisk.

Peter Kopp, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Speaker Bureau: Genzyme. Editorial Board involvement: Associate Editor Thyroid, Editorial Board Member Journal of Clinical Endocrinology and Metabolism.

John C. Morris, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Editorial Board Involvement: Associate Editor for Endocrine Practice

Elizabeth N. Pearce, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Editorial Board Involvement: Journal of Clinical Endocrinology & Metabolism; Endocrine Practice; European Journal of Clinical Nutrition; Board of directors: International Council for the Control of Iodine Deficiency Disorders.

David H. Sarne, MD discloses significant financial interests or other relationships with commercial interests in the following areas: an equity interest in Johnson & Johnson and General Electric.

R. Michael Tuttle, MD discloses significant financial interests or other relationships with commercial interests in the following areas: Grants/Research Support: None. Consultant: Genzyme, Novo Nordisk, Veracyte. Editorial Board Involvement: None.

Barbara R. Smith, CAE discloses no significant financial interests or other relationships with commercial interests.